title: Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma.
abstract: BACKGROUND
  Recent experience with thalidomide maintenance after high-dose chemotherapy with autologous stem cell support has demonstrated improvement in progression-free survival (PFS) and overall survival (OS). We further explored the tolerability and efficacy of lower doses of maintenance thalidomide in this single-institution study.
  
  
  METHODS
  Thirty-eight patients with myeloma were enrolled and treated with melphalan 200 mg/m(2) followed by autologous stem cell transplantation. Thalidomide 50 mg per day was started on day > or = 60 after recovery of blood counts and was escalated to a maximum dose of 200 mg per day. Responses were assessed at 2 months, 1 year, and 2 years after transplantation.
  
  
  RESULTS
  Of the 38 enrolled patients, 7 patients never received thalidomide. Among 31 patients receiving thalidomide, complete or very good partial responses were observed in 65% and 42% of patients at 1 and 2 years, respectively. Tolerability was a major issue, with only 17 patients completing 1 year of thalidomide. The goal of dosing 200 mg per day was achieved in just 17 of 31 patients, and the median tolerated thalidomide dose was 100 mg per day. Sensory neuropathy was the primary reason for dose modification and discontinuation. No thromboembolic events were observed. The median PFS was 20.8 months, and the median OS was > 60 months.
  
  
  CONCLUSIONS
  Thalidomide maintenance at a goal dose of 200 mg per day was not feasible in this population, with our data suggesting that 100 mg per day is a more reasonable maintenance dose.
authors.affiliation: School of Medicine and Public Health, University of Wisconsin, Madison, WI 53792, USA. jc2@medicine.wisc.edu
authors.forename: Julie E
authors.initials: JE
authors.lastname: Chang
authors.forename: Mark B
authors.initials: MB
authors.lastname: Juckett
authors.forename: Natalie S
authors.initials: NS
authors.lastname: Callander
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Gangnon
authors.forename: Teri L
authors.initials: TL
authors.lastname: Mitchell
authors.forename: Walter L
authors.initials: WL
authors.lastname: Longo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality* / Q000628:therapy*; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage*; D014182:Transplantation, Autologous
chemical_list: D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists; D013792:Thalidomide; D008558:Melphalan